The Study of Sleep Disordered Breathing in Patients With Interstitial Lung Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

69 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-25

Study Completion Date

2022-07-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was a cross-sectional observational study to evaluate the prevalence and predictive factors of SDB in ILD and to analyze the relationship between polysomnography (PSG) findings, pulmonary function, disease severity, parenchymal involvement, and sleep questionnaires ESS and SBQ. This study included 69 patients who were diagnosed with diffuse parenchymal lung diseases by high-resolution computed tomography (HRCT) chest. All patients were subjected to clinical examination, HRCT, spirometry, full-night polysomnography, and echocardiography.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Obstructive Sleep Apnea Prevalence in Patients With Chronic Obstructive Pulmonary Diseases

NCT04903639

OSA

COMPLETED

Predictors of OSA in Patients With COPD

NCT05605431

OSA COPD

COMPLETED

Exploring the Patterns of Sleep Disordered Breathing in Systemic Sclerosis Patients

NCT07175246

Systemic Sclerosis Sleep-Disordered Breathing

NOT_YET_RECRUITING

Sleep Disorders in Idiopathic Pulmonary Fibrosis

NCT05113654

Idiopathic Pulmonary Fibrosis

COMPLETED

Interstitial Lung Disease and Obstructive Sleep Apnea

NCT05838183

ILD OSA

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obstructive Sleep Apnea-hypopnea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OSA group

The group of patients who had sleep disordered breathing

Polysomnography

Intervention Type DIAGNOSTIC_TEST

Polysomnography is done for patients to find any sleep disordered breathing

No OSA group

The group of patients who had not sleep disordered breathing

Polysomnography

Intervention Type DIAGNOSTIC_TEST

Polysomnography is done for patients to find any sleep disordered breathing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Polysomnography

Polysomnography is done for patients to find any sleep disordered breathing

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sleep study

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Both sexes of clinically stable ILD patients older than 18 who met the ATS/ERS criteria for an ILD diagnosis were included in the study.

Exclusion Criteria

* Patients who have any anatomic upper airway obstructions such as significant nasal septal deviation, nasal polyps, conchae hypertrophy or tonsillar hypertrophy.
* Patients with neurological diseases or severe psychiatric disorders.
* Patients who have history of administration of any drug that has a major effect on sleep e.g. benzodiazepine, narcotic drugs ….etc.
* Patients with any chronic pulmonary disease except ILD.
* Total sleep time less than 4 hours on PSG.

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No